Omkar Spl.Chem.

- The company does not anticipate any major CAPEX going forward; only modest maintenance and debottlenecking CAPEX of around Rs. 5-5.5 crores is expected for the year (Page 8). - There is no mention of any planned new equity fundraising; promoter holding is stable at 58% with no plan for further dilution (Page 5). - The company is focused on gradually reducing debt by repaying about Rs. 20 crores annually; long-term debts are being repaid quarter-on-quarter (Page 10). - Debt reduction to zero is expected over 4-5 years if current repayment rate continues, with potential to pre-close debt earlier due to growing revenues (Page 10). - Some promoter loans are used temporarily for de-pledging shares but these will reduce when shares are de-pledged (Pages 17-19). - The company is using non-fund based loans and export packing credit to reduce interest costs (Page 6).

- Major CAPEX is largely completed; no major new CAPEX anticipated. - Planned maintenance CAPEX and plant debottlenecking expected to be modest, around Rs. 5-5.5 crores for the full year. - Unit #5 (Chiplun facility) with 4,500 MT capacity expected to be commissioned in the current financial year and will merge with LASA Laboratories. - Unit #6 capacity expanding from 300 MT to 750 MT, with part of it already operational within the current year. - Additional capacities totaling approx. 5,350 MT expected to come online this year, increasing total capacity to about 10,750 MT. - No significant strategic investments mentioned beyond capacity expansions and operational improvements. - Debt of Rs. 35 crores taken for Unit #5 CAPEX, which will be added to LASA's debt upon demerger. - Outsourcing for specialty chemicals and APIs initiated; forward integration into formulations on LASA side expected in current year.

- The company targets a conservative sales growth of 12%-15% based on existing capacities and products (Page 8, 18). - New developments, including commissioning of Unit #5 and outsourcing initiatives, are expected to add incremental growth beyond the baseline, potentially accelerating growth further (Page 14, 18). - Outsourcing business is anticipated to contribute Rs. 20-25 crores, roughly 10% addition to topline, potentially lifting overall growth close to 20%-25% (Page 18). - Unit #5 commissioning in the current financial year will increase capacity significantly, expected to boost sales and growth (Page 9, 14). - Exports are expected to improve from Q2 onwards, aiming for 25%-30% of total revenues, contributing to growth (Page 6). - New product approvals and launches (5-6 approved, 5-6 in pipeline) will also support future revenue increase (Page 6). - Overall, the company is confident of meeting or exceeding the 12%-15% growth guidance with new capacity and product additions.

- Omkar Speciality Chemicals Limited targets a conservative growth of 12%-15% annually based on existing capacities and products. (Page 6, 8, 13, 18) - New developments such as commissioning of Unit #5 and new product approvals are expected to accelerate growth beyond the current 12%-15% guidance. (Pages 13, 18) - EBIT margins are maintained around 20%, with occasional quarterly variations depending on product mix; EBITDA margins for Vet API business are around 25%-27%. (Pages 13, 18) - Exports are expected to increase from about 10%-12% to 25%-30% of revenues, contributing to growth and better receivables management. (Page 6, 11) - The company expects improved cash flows and profitability, enabling faster debt repayment possibly ahead of the estimated 4-5 years timeline. (Pages 10, 18) - EPS and operating profits should grow in line with topline growth and margin maintenance, with further upside from new capacities and products.

- The company has an order book equivalent to about two months of orders on hand. - There is clear visibility of order requirements from major customers for approximately two quarters. - Customers typically share their expected quantities for up to December in advance to help in planning raw materials and capacity. - Orders are received as per customer requirements, ensuring steady production planning. - This applies to existing as well as upcoming capacities such as Unit #5, which will add fungible production capacity usable across products. - Overall, the company maintains a healthy order position with visibility extending at least two quarters ahead.